Category: Pakistan
Terrestar Launches Canada-Wide Hybrid Satellite IoT Service Powered by Mavenir’s Cloud-Native Virtualized RAN and Core
Commercial launch marks a milestone for 3GPP standards-based Non-Terrestrial Network (NTN) services MONTRÉAL, Feb. 11, 2026 (GLOBE NEWSWIRE) — Terrestar Solutions Inc., Canada’s only domestically
Terrestar Launches Canada-Wide Hybrid Satellite IoT Service Powered by Mavenir’s Cloud-Native Virtualized RAN and Core
Commercial launch marks a milestone for 3GPP standards-based Non-Terrestrial Network (NTN) services MONTRÉAL, Feb. 11, 2026 (GLOBE NEWSWIRE) — Terrestar Solutions Inc., Canada’s only domestically
Terrestar Launches Canada-Wide Hybrid Satellite IoT Service Powered by Mavenir’s Cloud-Native Virtualized RAN and Core
Commercial launch marks a milestone for 3GPP standards-based Non-Terrestrial Network (NTN) services MONTRÉAL, Feb. 11, 2026 (GLOBE NEWSWIRE) — Terrestar Solutions Inc., Canada’s only domestically
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior